Condition: Diabetic Macular Edema · Sponsor: Frontera Therapeutics
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with Diabetic Macular Edema (DME). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.
This description comes directly from the study's public registry record.
Xinyan Li · +86-021-58206061 · Xinyan.li@fronteratherapeutics.com
Mignhui Xue · +86-021-58206061 · minghui.xue@fronteratherapeutics.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Eye Hospital | Tianjin, Tianjin,China, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06492876